Invention Grant
- Patent Title: Agents and methods to elicit anti-tumor immune response
-
Application No.: US16579583Application Date: 2019-09-23
-
Publication No.: US10822588B2Publication Date: 2020-11-03
- Inventor: Hua Gu , Richard Hodes , Jeffrey J. Chiang , Ihnkyung Jang
- Applicant: The Trustees of Columbia University in the City of New York , The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicant Address: US NY New York US MD Rockville
- Assignee: The Trustees of Columbia University in the City of New York,The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee: The Trustees of Columbia University in the City of New York,The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee Address: US NY New York US MD Rockville
- Agency: Wilmer Cutler Pickering Hale and Dorr LLP
- Main IPC: C12N5/0783
- IPC: C12N5/0783 ; C12N15/113 ; G01N33/50 ; C12Q1/25 ; A61K39/00
Abstract:
The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8+ T cells, (b) reducing Cbl-b activity in the CD8+ T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8+ T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.
Information query
